Welcome to LookChem.com Sign In|Join Free

CAS

  • or

801283-95-4

Faldaprevir is a hepatitis C virus protease inhibitor, a chemical compound specifically designed to combat chronic hepatitis C infection in adults. It functions by inhibiting the protease enzyme of the hepatitis C virus, thereby preventing the virus from replicating and spreading within the body. This action leads to a reduction in viral load and an improvement in liver function, making it a crucial component in the treatment of certain genotypes of the hepatitis C virus.

801283-95-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 801283-95-4 Structure

  • Basic information

    1. Product Name: Faldaprevir
    2. Synonyms: BI 201335;Faldaprevir;Faldaprevir(BI 201335);(1R,2S)-N-[(Cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-cyclopropanecarboxylic acid
    3. CAS NO:801283-95-4
    4. Molecular Formula: C40H49BrN6O9S
    5. Molecular Weight: 869.82
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 801283-95-4.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Faldaprevir(CAS DataBase Reference)
    10. NIST Chemistry Reference: Faldaprevir(801283-95-4)
    11. EPA Substance Registry System: Faldaprevir(801283-95-4)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 801283-95-4(Hazardous Substances Data)

801283-95-4 Usage

Uses

Used in Pharmaceutical Industry:
Faldaprevir is used as an antiviral medication for the treatment of chronic hepatitis C infection in adults. It is particularly effective in targeting and inhibiting the protease enzyme of the hepatitis C virus, which is essential for the virus's replication and spread. By doing so, Faldaprevir helps to reduce the viral load in the blood and improve liver function, offering a significant therapeutic benefit to patients suffering from this condition.
Additionally, Faldaprevir is often used in combination with other antiviral medications to enhance the overall effectiveness of treatment. This combined approach can lead to a more comprehensive and efficient management of the infection, increasing the chances of a successful treatment outcome.

Check Digit Verification of cas no

The CAS Registry Mumber 801283-95-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,1,2,8 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 801283-95:
(8*8)+(7*0)+(6*1)+(5*2)+(4*8)+(3*3)+(2*9)+(1*5)=144
144 % 10 = 4
So 801283-95-4 is a valid CAS Registry Number.

801283-95-4Downstream Products

801283-95-4Relevant articles and documents

Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)

Llinàs-Brunet, Montse,Bailey, Murray D.,Goudreau, Nathalie,Bhardwaj, Punit K.,Bordeleau, Josée,B?s, Michael,Bousquet, Yves,Cordingley, Michael G.,Duan, Jiamin,Forgione, Pat,Garneau, Michel,Ghiro, Elise,Gorys, Vida,Goulet, Sylvie,Halmos, Ted,Kawai, Stephen H.,Naud, Julie,Poupart, Marc-André,White, Peter W.

experimental part, p. 6466 - 6476 (2010/11/04)

C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these

CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR

-

Page/Page column 31, (2010/04/25)

This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 801283-95-4